Can new therapies save kidneys in myeloma patients?
NCT ID NCT06483139
First seen Nov 19, 2025 · Last updated May 06, 2026 · Updated 21 times
Summary
This study looks at whether plasma exchange or newer drugs like daratumumab can help the kidneys recover in people with multiple myeloma who have a type of kidney damage called light chain cast nephropathy. About 450 adults with this condition will be followed for 90 days to see who survives with improved kidney function. The goal is to find the best way to reduce the need for dialysis and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02130, United States
Contact
Conditions
Explore the condition pages connected to this study.